BioCentury This WeekWUSA9
About The Show Meet The Team Program Archive Become a Sponsor
UPDATE FLASH PLAYER AND EXPERIENCE THE NEW BCTV SHOW GUIDE

Mobile Banner Image


      HOME     ABOUT BIOCENTURY     WHY BCTV?     PRESS RELEASES    FREE CONTENT    LINK TO BCTV    CONTACT US   
Advertisement



BIOCENTURY EXTRA LATEST HEADLINES


   TOP STORY

Rep. Upton updates 21st Century Cures timeline

Rep. Fred Upton (R-Mich.) said he plans to release a discussion draft in mid-January 2015 of legislation based on the 21st Century Cures initiative he and Rep. Diana DeGette (D-Colo.) launched in May. more >>

   COMPANY NEWS

CHMP gives nod to AbbVie's HCV therapies

EMA's CHMP recommended approval of Exviera dasabuvir and Viekirax, which is a two direct-acting-antiviral (2-DAA) combination of ombitasvir and paritaprevir (ABT-450) plus the booster Norvir ritonavir from AbbVie Inc. (NYSE:ABBV) to treat chronic HCV infection. more >>

CHMP backs psoriasis treatments from Novartis, Celgene

EMA's CHMP recommended marketing authorization for Cosentyx secukinumab from Novartis AG (NYSE:NVS; SIX:NOVN) as a first-line treatment for adults with moderate to severe plaque psoriasis and Otezla apremilast from Celgene Corp. (NASDAQ:CELG) to treat active psoriatic arthritis and moderate to severe chronic plaque psoriasis in adults. CHMP said marketing authorization for both products would include a pharmacovigilance plan. more >>

CHMP supports Boehringer's nintedanib for IPF

EMA's CHMP recommended marketing authorization of Ofev nintedanib from Boehringer Ingelheim GmbH (Ingelheim, Germany) for the treatment of idiopathic pulmonary fibrosis (IPF). The compound is under accelerated assessment in the EU. more >>

Genzyme's Cerdelga gets CHMP nod for Gaucher's

EMA's CHMP recommended marketing authorization of Cerdelga eliglustat tartrate from the Genzyme Corp. unit of Sanofi (Euronext:SAN; NYSE:SNY) to treat Type I Gaucher's disease. more >>

Boehringer, WellPoint studying outcomes in AF

Boehringer Ingelheim GmbH (Ingelheim, Germany) and the HealthCore Inc. unit of WellPoint Inc. (NYSE:WLP) have identified non-valvular atrial fibrillation (NVAF) as the first project under their July deal to collaborate on the collection of real world health economic and outcomes data. more >>

G-BA: No additional benefit for Tecfidera in MS

Germany's Federal Joint Committee (G-BA) has concurred with the Institute for Quality and Efficiency in Healthcare (IQWiG) that Tecfidera dimethyl fumarate from Biogen Idec Inc. (NASDAQ:BIIB) offers no additional benefit over interferon beta-1a to treat relapsing-remitting multiple sclerosis (RRMS). more >>

   FINANCIAL NEWS

Lexicon raises $130M in follow-on and notes

Lexicon Pharmaceuticals Inc. (NASDAQ:LXRX) raised $80 million through the sale of senior convertible notes and $50 million in a follow-on through the sale of 49.8 million shares at $1. JP Morgan; Goldman Sachs; Needham; and Stifel, Nicolaus are underwriters. more >>

Banker tracks

Dresner Partners hired Robert Friedman as managing director, healthcare. Friedman was most recently managing director at Northeast Securities, and previously co-head of healthcare investment banking for Burnham Securities. more >>

   POLITICS & POLICY

Woodcock: Breakthrough designation mostly about efficacy

FDA awards or denies breakthrough designation requests primarily based on convincing clinical evidence of substantial efficacy or lack thereof, Janet Woodcock said Friday at a conference organized by Friends of Cancer Research and the Brookings Institution. Woodcock is director of the agency's Center for Drug Evaluation and Research. more >>

CMS issues final guidance on CED program

The Centers for Medicare & Medicaid Services (CMS) issued final guidance on its coverage with evidence development (CED) program that clarifies the program's stopping rules. more >>

FDA to hold workshop on LDT guidance

FDA will hold a public workshop on Jan. 8 and 9 in Bethesda, Md., to discuss its proposal for a risk-based framework to address regulatory oversight of laboratory developed tests (LDTs). The agency plans to discuss with stakeholders how to balance patient safety and access to LDTs. more >>

FDA workshop on therapies for rare patient subsets

FDA will hold a public workshop on Dec. 12 to discuss approaches to evaluate precision therapies targeting subsets of patients with rare molecular characteristics. The Center for Translational and Regulatory Sciences at the University of Virginia will co-sponsor the workshop, entitled "Developing and Using Precision Therapies in the 'Omics' Era: Generating and Interpreting Evidence for Rare Subsets." more >>

Advertisement

SCIBX: SCIENCE-BUSINESS EXCHANGE

SCIBX: SCIENCE-BUSINESS EXCHANGE
COVER STORY

Tapping TOPK

OncoTherapy Science has a potent TOPK inhibitor in a liposomal formulation that avoids the toxicity of other cytokinesis-targeted compounds.

TOOLS

Paperback diagnostics

A paper-based diagnostic using RNA switches could provide an easily distributed, rapid test for infectious diseases in point-of-care settings.

HemoShear's human touch

HemoShear's in vitro tumor model shows a new application for its tissue modeling technology and could open it to business from oncology companies.

TRANSLATIONAL NOTES

Mixing it up at Karolinska

Karolinska's new deputy vice chancellor, Alexander von Gabain, has plans to break down silos and breed new mindsets to maximize the institute’s translational potential.

THERAPEUTICS

This Week in Therapeutics

Overcoming oncogenic KRAS-driven chemotherapy resistance by blocking NRF2 signaling; trifunctional arylpiperazine analogs as antipsychotic agents; inhibiting TRPM2 or RAC1 to treat ischemic kidney injury; and more...

TECHNIQUES

This Week in Techniques

Lysyl oxidase to enhance tensile properties of musculoskeletal grafts; a sorbitol-based PET imaging agent to help diagnose and monitor Enterobacteriaceae infections; genetic variants near estrogen receptor-alpha to predict the risk of breast cancer in Latina women; and more...

User Agreement | Terms of Use | Privacy Policy | Your California Privacy Rights | Use of Images

Advertisement